Clinical Trial: Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801703) titled 'Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression' on Aug. 31.

Brief Summary: The goal of this clinical trial is to see if combining ketamine with behavioral activation (BA) therapy to treat moderate to severe treatment-resistant depression improves depressive symptoms and general functioning more than ketamine alone.

We aim to find out whether participants who receive both treatments:

1. Have greater reductions in depression symptoms than those who receive ketamine only

2. Have better response and remission rates than those who receive ketamine only

3. Experience better overall functioning, includin...